Search all articles within the Institute for Biomedicine and Glycomics topic
A next-generation COVID-19 mucosal vaccine is set to be a gamechanger not only when delivering the vaccine itself, but also for people who are needle-phobic.
Professor Paul Clarke will join the University as the inaugural Executive Director of the new Institute for Biomedicine and Glycomics.
A $2 million grant awarded to establish the Queensland Drug Discovery Alliance (QDDA) will align and grow Queensland’s small molecule therapeutic discovery capability under the leadership of Therapeutic Innovation Australia (TIA).
In a groundbreaking effort to combat the devastating effects of Spinal Muscular Atrophy (SMA), Dr. Jean Giacomotto from the Griffith...
Native Charge Detection Mass Spectrometry will enable cross-collaboration research to develop life-changing therapies, vaccines and diagnostics.
Griffith University has been awarded $2.2 million across the National Health and Medical Research Council (NHMRC) Investigator Grants. Congratulations to...
Griffith researchers among 19 scientists share in $5.56 million of funding.
Researchers develop drug target to tackle multi-drug resistant lung bacterium.
Griffith University will use a $2.95 million NHMRC grant to take a unique focus on targeting sugar interactions to prevent...
We’re excited to announce the launch of the Bourne Foundation Nuclear Magnetic Resonance (NMR) Facility, an institute core facility that...
